Symbiosis Pharmaceutical Services, a worldwide sterile fill/finish contract manufacturing organization (CMO), has successfully passed its recent audit conducted by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This follows an inspection of its newly constructed Bruce Building, a 20,000 sq ft aseptic facility that contains an automated fill/finish line for the sterile production of injectable drug products, including both small molecules and biologics.

This successful audit marks another step in Symbiosis’ £26 million strategic investment to scale its commercial manufacturing capabilities.

Formally opened by Scotland’s Deputy First Minister Kate Forbes in late 2024, the new expanded GMP facility enhances Symbiosis’ ability to deliver:

• Aseptic fill/finish of liquid parenteral drug products
• Handling of cytotoxic and high-potency compounds
• Scalable batch sizes from preclinical to commercial

This regulatory endorsement reinforces Symbiosis’ commitment to global quality standards and strengthens its position as a trusted partner to biotechnology and pharmaceutical companies worldwide.

“This extension of our current MHRA licenses reflects the strength of our team and the robustness of our quality systems. For our clients, this solidifies confidence in our ability to accelerate the delivery of their sterile drug products to patients worldwide within a tightly regulated landscape,” said Colin MacKay, CEO of Symbiosis.